Regeneron Pharmaceuticals
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works.
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT05744921
- Locations
- ๐จ๐ณ
Chang Gung Memorial Hospital- Linkou Branch, Taoyuan, Taiwan
๐จ๐ฆToronto General Hospital, Toronto, Ontario, Canada
๐ญ๐บSemmelweis University/Semmelweis Egyetem, Budapest, Hungary
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT05730036
- Locations
- ๐ง๐ช
Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Antwerp, Belgium
๐ต๐ฑSamodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie, Poland
๐บ๐ธUCLA, Los Angeles, California, United States
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT05685173
- Locations
- ๐ซ๐ท
Hopital Saint-Louis, Paris, Cedex 10, France
๐ช๐ธHospital Vall d'Hebron, Barcelona, Spain
๐บ๐ธRutgers Cancer Institute of New Jersey., New Brunswick, New Jersey, United States
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT05673967
- Locations
- ๐บ๐ธ
Regeneron Research Facility, Tarrytown, New York, United States
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD)
- Conditions
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT05648214
- Locations
- ๐บ๐ธ
California Clinical Trials Medical Group, Glendale, California, United States
๐บ๐ธMed Research of Florida,LLC, Miami, Florida, United States
๐บ๐ธVelocity Clinical research, Los Angeles, California, United States
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 373
- Registration Number
- NCT05618808
- Locations
- ๐ง๐ฌ
MBAL Heart and Brain Hospital, Pleven, Bulgaria
๐ง๐ชZiekenhuis Oost-Limburg- Campus Sint-Jan, Genk, Limburg, Belgium
๐ญ๐บDepartment of Orthopedics, Somogy County Mรณr Kaposi Teaching Hospital, Kaposvar, Hungary
A Compassionate Use (CU) Program of Odronextamab
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT05619367
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1530
- Registration Number
- NCT05608291
- Locations
- ๐บ๐ธ
UCSF Medical Center, Investigational Pharmacy, San Francisco, California, United States
๐บ๐ธUniversity of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธCancer Center IDS UVA Cancer Center IDS Pharmacy, Charlottesville, Virginia, United States
A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05603195
- Locations
- ๐ฌ๐ง
Labcorp Clinical Research Unit, Leeds, United Kingdom
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT05590585
- Locations
- ๐บ๐ธ
Skin and Cancer Associates, LLP, Miami, Florida, United States
๐บ๐ธC2 Research Center, LLC, Montgomery, Alabama, United States
๐บ๐ธOregon Health & Science University, Portland, Oregon, United States